PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
0.07
%
7,71%
Latest
0.978
High
0.978
Low
0.908
Volume
3 570
Turnover (SEK)
3 305
Market Value (MSEK)
29,1
Time (Latest trade)
2022-12-02 17:06

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Arne Skogvall 33,13 33,13 2022-09-28
Staffan Skogvall 9,93 9,93 2022-10-18
Avanza Pension 1,65 1,65 2022-09-28
Vict Th Engwalls Stiftelse 1,63 1,63 2022-09-28
Henrik Skog 1,57 1,57 2022-09-28
Arian Ismail 1,30 1,30 2022-09-28
Nordnet Pensionsförsäkring 1,05 1,05 2022-09-28
Staffan Engelbert Bodén 0,80 0,80 2022-09-28
Tommy Johansson 0,67 0,67 2022-09-28
Torsten Ingemar Jonsson 0,67 0,67 2022-09-28
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2023-02-16 Bokslutskommuniké 2022

Annual reports, prospectus etc.